Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Minoxidil 2% vs minoxidil 5% Proportion of participants with investigator‐rated clinically significant hair regrowth · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 3 studies · 586 participants | Moderate |
Minoxidil 2% vs minoxidil 5% Change from baseline to study conclusion in total hair count · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 3 studies · 631 participants | Low |
Minoxidil 2% vs minoxidil 5% Degree of hair shedding from baseline to the end of the study ‐ not measured · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Minoxidil 2% vs minoxidil 5% Cosmetic appearance of the hair or participant satisfaction · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 322 participants | Moderate |
Minoxidil 2% vs minoxidil 5% Change in quality (or pattern) of hair regrowth (e.g. thickness) · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 322 participants | Moderate |
Finasteride vs placebo The proportion of participants with self‐rated clinically significant hair regrowth at the end of the study · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | RR 0.95 [0.66, 1.37] | 1 study · 137 participants | Low |
Finasteride vs placebo Change in quality of life ‐ not measured · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Finasteride vs placebo Adverse events · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | RR 1.03 [0.45, 2.34] | 1 study · 137 participants | Low |
Minoxidil vs placebo Change in quality of life · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 1 study · 260 participants | Low |
Finasteride vs placebo Proportion of participants with investigator‐rated clinically significant hair regrowth · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | RR 0.77 [0.31, 1.9] | 1 study · 137 participants | Low |
Finasteride vs placebo Change from baseline to study conclusion in total hair count · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 3 studies · 231 participants | Low |
Finasteride vs placebo Degree of hair shedding from baseline to the end of the study · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 1 study · 137 participants | Low |
Finasteride vs placebo Cosmetic appearance of the hair or participant satisfaction · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | RR 0.78 [0.4, 1.53] | 1 study · 137 participants | Low |
Finasteride vs placebo Change in quality (or pattern) of hair regrowth (e.g. thickness) ‐ not measured · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Low‐level laser comb vs sham device Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 141 participants | Moderate |
Low‐level laser comb vs sham device Change in quality of life ‐ not measured · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Low‐level laser comb vs sham device Adverse events · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 141 participants | Low |
Low‐level laser comb vs sham device Participants with investigator‐rated clinically significant hair regrowth ‐ not measured · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Low‐level laser comb vs sham device Change from baseline to study conclusion in total hair count · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 122 participants | Low |
Minoxidil vs placebo Adverse events · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | RR 1.24 [0.82, 1.87] | 4 studies · 727 participants | Low |
Low‐level laser comb vs sham device Degree of hair shedding from baseline to the end of the study ‐ not measured · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Low‐level laser comb vs sham device Cosmetic appearance of the hair or participant satisfaction · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 141 participants | Moderate |
Low‐level laser comb vs sham device Change in quality (or pattern) of hair regrowth (e.g. thickness) ‐ not measured · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Minoxidil vs placebo Proportion of participants with investigator‐rated clinically significant hair regrowth at the end of the study · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | RR 2.35 [1.68, 3.28] | 7 studies · 1181 participants | Moderate |
Minoxidil vs placebo Change from baseline in total hair count · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 8 studies · 1242 participants | Low |
Minoxidil vs placebo Degree of hair shedding from baseline to the end of the study · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 3 studies · 380 participants | Very low |
Minoxidil vs placebo Cosmetic appearance of the hair or participant satisfaction · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 1 study · 260 participants | Low |
Minoxidil vs placebo Change in quality (or pattern) of hair regrowth (e.g. thickness) · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 372 participants | Low |
Minoxidil 2% vs minoxidil 5% Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL Interventions for female pattern hair loss (2016) · Cochrane | no estimate extracted | 2 studies · 322 participants | Low |
Light therapies (including photodynamic therapy) vs placebo, no treatment, topical treatment and other comparators Participant's global assessment of improvement Non‐standardised scales · Mild, moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 23 studies · 1033 participants | Very low |
MAL‐PDT vs red light only Investigator's global assessment (IGA) of improvement Treatment 'success' as defined by IGA score decrease5 · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | RR 1.74 [1.11, 2.74] | 3 studies · 360 participants | Moderate |
ALA‐PDT vs blue light only Participant's global assessment of improvement Non‐standardised scale5 · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | RR 0.87 [0.72, 1.04] | 1 study · 266 participants | Low |
ALA‐PDT vs blue light only Investigator‐assessed change in inflamed lesions (ILs) Lesion counts · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 1 study · 266 participants | Very low |
ALA‐PDT vs blue light only Investigator‐assessed percentage change in ILs Lesion counts · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 1 study · 266 participants | Very low |
ALA‐PDT vs blue light only Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 1 study · 266 participants | Very low |
ALA‐PDT vs blue light only Investigator's global assessment (IGA) of improvement Treatment 'success' as defined by IGA score decrease6 · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | RR 0.81 [0.51, 1.29] | 1 study · 266 participants | Low |
Light therapies (including photodynamic therapy) vs placebo, no treatment, topical treatment and other comparators Investigator‐assessed change in lesion counts Lesion counts · Mild, moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 51 studies · 2242 participants | Very low |
Light therapies (including photodynamic therapy) vs placebo, no treatment, topical treatment and other comparators Investigator‐assessed severe adverse effects Blistering or scarring · Mild, moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 66 studies · 3945 participants | Very low |
MAL‐PDT vs red light only Paticipant's global assessment of improvement ‐ Not measured · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | NR | No studies |
MAL‐PDT vs red light only Investigator‐assessed change in inflamed lesions (ILs) Lesion counts · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 3 studies · 360 participants | Moderate |
MAL‐PDT vs red light only Investigator‐assessed change in non‐inflamed lesions (NILs) Lesion counts · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 3 studies · 360 participants | Moderate |
MAL‐PDT vs red light only Investigator‐assessed percentage change in ILs Lesion counts · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 3 studies · 360 participants | Moderate |
MAL‐PDT vs red light only Investigator‐assessed percentage change in NILs Lesion counts · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 3 studies · 360 participants | Moderate |
MAL‐PDT vs red light only Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris Light therapies for acne (2016) · Cochrane | no estimate extracted | 3 studies · 360 participants | Moderate |
Specific allergen immunotherapy vs no immunotherapy Participant‐ or parent‐reported global assessment of disease severity · adults and children with atopic eczema and inhalant allergen sensitisation Specific allergen immunotherapy for the treatment of atopic eczema (2016) · Cochrane | no estimate extracted | 2 studies · 44 participants | Low |
Specific allergen immunotherapy vs no immunotherapy Participant‐ or parent‐reported specific symptoms of eczema · adults and children with atopic eczema and inhalant allergen sensitisation Specific allergen immunotherapy for the treatment of atopic eczema (2016) · Cochrane | no estimate extracted | 6 studies · 339 participants | Very low |
Specific allergen immunotherapy vs no immunotherapy Adverse events ‐ any systemic reaction · adults and children with atopic eczema and inhalant allergen sensitisation Specific allergen immunotherapy for the treatment of atopic eczema (2016) · Cochrane | RR 0.78 [0.41, 1.49] | 7 studies · 492 participants | Moderate |
Specific allergen immunotherapy vs no immunotherapy Investigator‐ or physician‐rated global assessment of disease severity · adults and children with atopic eczema and inhalant allergen sensitisation Specific allergen immunotherapy for the treatment of atopic eczema (2016) · Cochrane | RR 1.48 [1.16, 1.88] | 7 studies · 286 participants | Very low |
Specific allergen immunotherapy vs no immunotherapy Investigator‐ or physician‐rated eczema severity using a published scale · adults and children with atopic eczema and inhalant allergen sensitisation Specific allergen immunotherapy for the treatment of atopic eczema (2016) · Cochrane | no estimate extracted | 6 studies · 435 participants | Very low |
Specific allergen immunotherapy vs no immunotherapy Participant or parent‐rated eczema severity using a published scale · adults and children with atopic eczema and inhalant allergen sensitisation Specific allergen immunotherapy for the treatment of atopic eczema (2016) · Cochrane | no estimate extracted | 2 studies · 184 participants | Low |